Core Xarelto Patents and Expiry Dates
Xarelto (rivaroxaban), made by Bayer and Janssen, has its primary composition of matter patent US 7,157,456 expired on September 30, 2024, in the US. This covers the drug's basic chemical structure.[1][2]
When Do Key Formulation Patents Expire?
Later patents extend protection for specific formulations and uses:
- US 7,592,339 (crystalline forms) expires December 29, 2026.
- US 7,585,860 (dosage regimens) expires October 3, 2026.
- Pediatric exclusivity adds six months to some, pushing effective expiry to mid-2027.[1][3]
These block generics until resolved.
Biosimilar and Generic Entry Timeline
No generics launched by late 2024 due to ongoing litigation. Bayer settled with some ANDA filers (e.g., Mylan, Sandoz) for entry as early as April 2026, others later. The FDA's first tentative approval came in 2023, but full approval awaits patent cliffs.[2][4]
Why Multiple Patents and Challenges?
Xarelto faces over 100 Paragraph IV challenges from generics makers alleging invalidity or non-infringement. Courts upheld most Bayer patents, delaying competition. Sales peaked at $7B+ annually before erosion starts.[1][3]
Global Patent Differences
- EU: Key patents expired 2023-2024; generics entered some markets like Germany.
- Japan: Main patent expired 2023.[2]
Impact on Patients and Pricing
Post-expiry, generics could cut US prices 80-90%, improving access for anticoagulation therapy. Current list price is ~$500/month; monitor for switches.[4]
[1]: DrugPatentWatch.com Xarelto patents
[2]: FDA Orange Book for rivaroxaban
[3]: USPTO patent database (search 7157456, 7592339)
[4]: FDA tentative approvals tracker